Individual patients' data meta-analyses in head and neck cancer

Current Opinion in Oncology

Volumn 19, Issue 3, 2007, Pages 188-194

  Bourhis, Jean ^a   Le Maître, Aurélie ^a   Baujat, Bertrand ^a   Audry, Hélène ^a   Pignon, Jean Pierre ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Altered fractionation; Chemotherapy; Head and neck cancer; Individual patient based meta analysis

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; PLATINUM DERIVATIVE;

AGING; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; HEAD AND NECK CANCER; HUMAN; LARYNGECTOMY; LARYNX CARCINOMA; META ANALYSIS; NASOPHARYNX CARCINOMA; PATIENT COMPLIANCE; PHARYNX CARCINOMA; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; REVIEW; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW;

CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; HYPOPHARYNGEAL NEOPLASMS; META-ANALYSIS; NASOPHARYNGEAL NEOPLASMS; NEOADJUVANT THERAPY;

EID: 34247161830     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3280f01010     Document Type: Review

References (29)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide IARC CancerBase No. 5. version 2.0. Lyon: IARC Press; 2004.
2. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 1993. CA Cancer J Clin 2000; 50:7-33.
3. Pignon JP, Bourhis J, Domenge C, Désigné L, on behalf of the MACH-NC Collaborative Group. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 2000; 355:949-955.
4. Pignon JP, Hill C. Meta-analysis of randomized clinical trials in oncology. Lancet Oncology 2001; 2:475-482.
5. Baujat B, Audry H, Bourhis J, et al., on behalf of the MAC-NPC Collaborative Group. Chemotherapy in locally advanced nasopharyngeal carcinoma. An individual patient data meta-analysis of 8 randomised trials and 1753 patients. Int J Rad Oncol Biol Phys 2006; 64:47-56. Among the different meta-analyses performed in NPC to evaluate the effect of chemotherapy, this is the only one based on the collection of updated individual patients' data from randomized trials. Concomitant chemo-radiotherapy was the most effective treatment combination.
6. Bourhis J, Overgaard J, Audry H, et al., on behalf of the Meta-Analysis of Radiotherapy in Carcinomas of Head and neck (MARCH) Collaborative Group. Hyperfractionated or accelerated radiotherapy in head and neck cancer: an individual patient data meta-analysis of 15 randomized trials. Lancet 2006; 368:843-854. This meta-analysis is based on the collection of updated individual HNSCC patients' data from randomized trials comparing conventional radiotherapy versus altered fractionated radiotherapy (accelerated and/or hyperfractionated). Altered fractionated radiotherapy was found to improve significantly both loco-regional control and survival; the hyperfractionated type of radiotherapy being the most effective regimen.
7. Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer: An overview of randomized trials. N Engl J Med 1995; 333:1444-1455.
8. Stewart LA, Parmar MK. Meta-analysis of the literature or of individual patient data: is there a difference? Lancet 1993; 341:418-422.
9. Baujat B, Mahé C, Pignon JP, Hill C. A graphical method for exploring heterogeneity in meta-analysis: application to a meta-analysis of 65 trials. Stat Med 2002; 21:2641-2652.
10. Bourhis J, Amand C, Pignon JP, on behalf of the MACH-NC Collaborative Group. Update of MACH-NC (Meta-Analysis of Chemotherapy in Head & Neck Cancer) database focused on concomitant chemoradiotherapy. Proc Am Soc Clin Oncol 2004; 22:488.
11. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350:1945-1952.
12. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350:1937-1944.
13. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998; 338:1798-1804.
14. Budach V, Stuschke M, Budach W, et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol 2005; 23:1125-1135.
15. Bensadoun RJ, Benezery K, Dassonville O, et al. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys 2006; 64:983-994.
16. Vermorken JB, Remenar E, Van Herpen C, et al. Standard cisplatin/infusional 5-fluorouracil vs docetaxel (T) plus PF as neoadjuvant chemotherapy for non resectable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): a phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971). Proc Am Soc Clin Oncol 2004; 22:490s. This report from the EORTC shows for the first time in a randomized study a survival advantage in favour of induction TPF, as compared with induction PF. In addition, the toxicity was slightly reduced with the TPF regimen.
17. Horiot JC, LeFur R, N'Guyen T, et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: Final analysis of a randomized trial of the EORTC cooperative group of RT. Radiother Oncol 1992; 25:231-241.
18. Overgaard J, Hansen HS, Specht L, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 2003; 362:933-940.
19. Bourhis J, Lapeyre M, Tortochaux J, et al. Very accelerated compared to conventional radiotherapy in HNSCC: results of a GORTEC, phase III randomized trial. J Clin Oncol 2006; 24:2873-2878.
20. Bourhis J, Le Maître A, Pignon J. MACH-NC, MARCH Groups. Impact of age on treatment effect in locally advanced head and neck cancer (HNC): two individual patient data meta-analyses [abstract]. Proc Am Soc Clin Oncol 2006; 24:280s.
21. Pignon JP, Syz N, Posner M, et al. Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck. Anticancer Drugs 2004; 15:331-340.
22. Calais G, Pointreau Y, Alfonsi M, et al. Randomized phase III trial comparing induction chemotherapy using cisplatin (P) fluorouracil (F) with or without docetaxel (T) for organ preservation in hypopharynx and larynx cancer. Preliminary results of GORTEC 2000-01. Proc Am Soc Clin Oncol 2006; 24:281s.
23. Haddad RI, Tishler R, Wirth L, et al. Rate of complete pathological responses (pCR) to docetaxel/cisplatin/5-fluorouracil (TPF) induction chemotherapy in patients with newly diagnosed, locally advanced squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol 2005; 23:502s.
24. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999; 91:2081-2086.
25. Denis F, Garaud P, Bardet E, et al. Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant chemo-radiotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys 2003; 55:93-98.
26. Chao KS, Ozyigit G, Blanco AI, et al. Intensity-modulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume. Int J Radiat Oncol Biol Phys 2004; 59:43-50.
27. Eisbruch A. Intensity-modulated radiation therapy in the treatment of head and neck cancer. Nat Clin Pract Oncol 2005; 2:34-39.
28. Bernier J, Bourhis J. Introducing the BECT (biologically enhanced cytotoxic treatment) concept in cancer treatment. Ann Oncol 2005; 16:1722.
29. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-578. This randomized trial showed that the combination of a molecular targeted drug with radiotherapy was superior to radiotherapy alone. This was a proof of concept which was obtained with EGFR targeting. In addition, there was no increase of 'in field' radiation toxicity associated with EGFR targeting.